Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

Abstract

Objective: To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease.

Design: Randomised, double blind, parallel group, placebo controlled trial.

Setting: 86 outpatient clinics in Europe and Canada.

Participants: 653 patients with mild to moderate Alzheimer's disease.

Intervention: Patients randomly assigned to galantamine had their daily dose escalated over three to four weeks to maintenance doses of 24 or 32 mg.

Main outcome measures: Scores on the 11 item cognitive subscale of the Alzheimer's disease assessment scale, the clinician's interview based impression of change plus caregiver input, and the disability assessment for dementia scale. The effect of apolipoprotein E4 genotype on reponse to treatment was also assessed.

Results: At six months, patients who received galantamine had a significantly better outcome on the 11 item cognitive subscale of the Alzheimer's disease assessment scale than patients in the placebo group (mean treatment effect 2.9 points for lower dose and 3.1 for higher dose, intention to treat analysis, P<0.001 for both doses). Galantamine was more effective than placebo on the clinician's interview based impression of change plus caregiver input (P<0.05 for both doses v placebo). At six months, patients in the higher dose galantamine group had significantly better scores on the disability assessment for dementia scale than patients in the placebo group (mean treatment effect 3.4 points, P<0.05). Apolipoprotein E genotype had no effect on the efficacy of galantamine. 80% (525) of patients completed the study.

Conclusion: Galantamine is effective and well tolerated in Alzheimer's disease. As galantamine slowed the decline of functional ability as well as cognition, its effects are likely to be clinically relevant.

Figure 1

Profile of trial

Figure 2

Mean (SE) change from baseline in score on 11 item cognitive subscale of Alzheimer's disease assessment scale over time, observed case analysis

Figure 3

Mean (SE) change in 11 item cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog/11) scores at six months according to baseline score on mini-mental state examination, observed case analysis